alluviretatrutide964170 - Profile

About me

Profile

Alluvi, formerly BI 4744, offers a promising advance in obesity care. This dual activator targeting both GLP-1 and GIP sites demonstrates compelling results in patient trials, potentially

https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/